1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Islet Cell Carcinoma (Insulinoma) Global Clinical Trials Review, H1, 2015

Islet Cell Carcinoma (Insulinoma) Global Clinical Trials Review, H1, 2015

  • February 2015
  • -
  • GlobalData
  • -
  • 106 pages

Summary

Table of Contents

Search Inside

Islet Cell Carcinoma (Insulinoma) Global Clinical Trials Review, H1, 2015

Summary

GlobalData's clinical trial report, “Islet Cell Carcinoma (Insulinoma) Global Clinical Trials Review, H1, 2015" provides data on the Islet Cell Carcinoma (Insulinoma) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Islet Cell Carcinoma (Insulinoma). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Islet Cell Carcinoma (Insulinoma). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market

Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market

  • $ 4995
  • Industry report
  • March 2017
  • by GBI Research

Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market Summary Many countries are facing the challenge ...

Global Cancer Supportive Care Therapeutics Market to 2022 - Patent Expirations Create Opportunities for Biosimilars in the Chemotherapy Induced Anemia and Neutropenia Markets

Global Cancer Supportive Care Therapeutics Market to 2022 - Patent Expirations Create Opportunities for Biosimilars in the Chemotherapy Induced Anemia and Neutropenia Markets

  • $ 4995
  • Industry report
  • March 2017
  • by GBI Research

Global Cancer Supportive Care Therapeutics Market to 2022 - Patent Expirations Create Opportunities for Biosimilars in the Chemotherapy Induced Anemia and Neutropenia Markets Summary Cancer is a disease ...

Global T-Cell Immunotherapy Pipeline Analysis, 2016 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Global T-Cell Immunotherapy Pipeline Analysis, 2016 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

  • $ 3900
  • Industry report
  • January 2017
  • by P&S Market Research

Pipeline Overview T-cell immunotherapy mainly consists of T-cell receptor (TCR), Tumor-infiltrating lymphocytes (TILs) and Chimeric antigen receptors (CAR) T-cell therapy. TCR is a complex integral membrane ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.